Pharmacokinetics of muscarinic cholinergic drugs as determined by ex vivo (3H)-oxotremorine-M binding.
The pharmacokinetic parameters of muscarinic cholinergic drugs after intravenous (IV) and oral administration to mice was determined with ex vivo (3H)-oxotremorine-M (3H-Oxt) binding to the brain. Oxotremorine had a long duration of action, and arecoline had a short one. There was a significant correlation between the ex vivo ED50 and the in vitro inhibition constants (Ki). Tremorine, a prodrug, inhibited ex vivo binding, but was relatively inactive in in vitro binding. The quaternary amines, methylscopolamine and oxotremorine-M, and the hydrophilic compound, pirenzepine, were relatively weak in inhibiting ex vivo binding because of their poor penetration of the blood-brain barrier. Oxotremorine and BM-5 were similarly bioavailable to the brain by the IV and the oral route. These results indicate that the pharmacokinetic profile of muscarinic cholinergic drugs can be determined with ex vivo (3H)-Oxt binding.
Sethy
V H
VH
CNS Disease Research, Upjohn Company, Kalamazoo, MI 49001.
Francis
J W
JW
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001682:Biological Availability; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D010095:Oxotremorine / Q000378:metabolism / Q000493:pharmacokinetics*; D010277:Parasympathomimetics / Q000493:pharmacokinetics*; D010890:Pirenzepine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014203:Tremorine / Q000494:pharmacology
D010277:Parasympathomimetics; D010890:Pirenzepine; D010095:Oxotremorine; D014203:Tremorine